While ERBB2/HER2 amplification and overexpression have been extensively studied in breast and gastric cancers, where they are associated with poor prognosis and aggressive tumor biology,20,21 their prevalence, prognostic significance, and therapeutic implications in other tumor types remain less well-defined. The gene discussed is ERBB2; the disease is neoplasm.